Pfizer
NEWS
kENUP had called the mRNA vaccine efforts in Africa “doomed to fail” since the project likely infringes on BioNTech and Moderna patents on the vaccine.
It’s uncertain if the origins of COVID-19 will ever be determined, but the current top theories split about evenly between a lab leak from the Wuhan Institute of Virology and a natural evolution from bats to animals to humans at a Wuhan “wet market.”
The COVID-19 pandemic has seen a full-blown effort from biopharma and researchers to develop new drugs and test old ones against the disease, with highly mixed results.
The vaccine delivered more than $12 billion in revenue to Pfizer and the company expects those earnings to vastly increase this year to $32 billion.
Here’s a look at five companies that produced non-vaccine treatments for COVID-19.
Antiviral pills against COVID-19 show promise for treating the disease, but they are not broadly accessible yet.
To address that lack of diversity, Medable and CVS have forged a collaboration to improve patient access to clinical trial research.
COVID-19 is a respiratory illness and presents many other symptoms, including blood clots. For more details and other COVID-19 news, continue reading.
FDA Action Alert for February 7
JOBS
IN THE PRESS